Company Overview
Abbott Laboratories is a diversified health care company based in the United States. It operates across diagnostics, medical devices, nutrition, and branded generic pharmaceuticals. The company develops and markets products that support patient care and chronic condition management globally. Abbott’s market capitalization is about USD 188 billion, supported by roughly 1.74 billion shares outstanding.
Analysis of recent data
FundamentalsIn reported USD figures, Abbott recorded revenue of USD 44.3 billion for the year ended 2025, representing 5.67% growth from the prior year. Depreciation and amortization totaled USD 1.68 billion, while cash holdings of USD 8.52 billion exceeded total debt of USD 6.07 billion, indicating a strong liquidity position.
Trailing margins remain solid, with operating margin 17.81% and net profit margin 14.72%. A gross margin of 56.68% and return on equity of 12.89% highlight a stable earnings base that supports reinvestment and product development.
EBIT, net income, and capital expenditure were not provided, limiting visibility into reinvestment trends. However, the company’s balance sheet flexibility and consistent revenue growth suggest continued operational stability.
Valuation
DCF / MultiplesAt a market price of USD 109.23, Abbott trades above its DCF fair value range of USD 50.29 (bear), USD 73.05 (base), and USD 98.61 (bull). This indicates that investors are pricing in sustained mid‑single‑digit growth and efficient reinvestment.
With a trailing PE of 28.77 and a gross margin of 56.68%, the valuation reflects confidence in the company’s ability to maintain profitability and reinvestment discipline. Any slowdown in growth could challenge these expectations.
Conclusion
TakeawayAbbott appears to be valued for steady performance rather than major surprises. The company’s strong balance sheet supports ongoing innovation. Investors seem comfortable paying a premium for consistency. Future results will show if that confidence is justified.